CN102174522B - Preparation method of protein 4-1BBL - Google Patents
Preparation method of protein 4-1BBL Download PDFInfo
- Publication number
- CN102174522B CN102174522B CN 201110045245 CN201110045245A CN102174522B CN 102174522 B CN102174522 B CN 102174522B CN 201110045245 CN201110045245 CN 201110045245 CN 201110045245 A CN201110045245 A CN 201110045245A CN 102174522 B CN102174522 B CN 102174522B
- Authority
- CN
- China
- Prior art keywords
- ttg
- 1bbl
- tct
- aga
- aac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000002627 4-1BB Ligand Human genes 0.000 title claims abstract description 55
- 108010082808 4-1BB Ligand Proteins 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 9
- 239000013612 plasmid Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000010839 reverse transcription Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000005336 cracking Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract description 3
- 125000000539 amino acid group Chemical group 0.000 abstract description 2
- 238000012407 engineering method Methods 0.000 abstract description 2
- 101000638253 Mus musculus Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108700031361 Brachyury Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 2
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MCKSLROAGSDNFC-ACZMJKKPSA-N Ala-Asp-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MCKSLROAGSDNFC-ACZMJKKPSA-N 0.000 description 1
- NKJBKNVQHBZUIX-ACZMJKKPSA-N Ala-Gln-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKJBKNVQHBZUIX-ACZMJKKPSA-N 0.000 description 1
- MTDDMSUUXNQMKK-BPNCWPANSA-N Ala-Tyr-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N MTDDMSUUXNQMKK-BPNCWPANSA-N 0.000 description 1
- KGSJCPBERYUXCN-BPNCWPANSA-N Arg-Ala-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KGSJCPBERYUXCN-BPNCWPANSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- FAEFJTCTNZTPHX-ACZMJKKPSA-N Asn-Gln-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FAEFJTCTNZTPHX-ACZMJKKPSA-N 0.000 description 1
- FMNBYVSGRCXWEK-FOHZUACHSA-N Asn-Thr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O FMNBYVSGRCXWEK-FOHZUACHSA-N 0.000 description 1
- UGKZHCBLMLSANF-CIUDSAMLSA-N Asp-Asn-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UGKZHCBLMLSANF-CIUDSAMLSA-N 0.000 description 1
- UGIBTKGQVWFTGX-BIIVOSGPSA-N Asp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O UGIBTKGQVWFTGX-BIIVOSGPSA-N 0.000 description 1
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 1
- MRYDJCIIVRXVGG-QEJZJMRPSA-N Asp-Trp-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O MRYDJCIIVRXVGG-QEJZJMRPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 1
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- UEGIPZAXNBYCCP-NKWVEPMBSA-N Gly-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)CN)C(=O)O UEGIPZAXNBYCCP-NKWVEPMBSA-N 0.000 description 1
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 1
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 1
- MREVELMMFOLESM-HOCLYGCPSA-N Gly-Trp-Val Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O MREVELMMFOLESM-HOCLYGCPSA-N 0.000 description 1
- SYMSVYVUSPSAAO-IHRRRGAJSA-N His-Arg-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O SYMSVYVUSPSAAO-IHRRRGAJSA-N 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 1
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 1
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- SQUFDMCWMFOEBA-KKUMJFAQSA-N Leu-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SQUFDMCWMFOEBA-KKUMJFAQSA-N 0.000 description 1
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 1
- UQRZFMQQXXJTTF-AVGNSLFASA-N Lys-Lys-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O UQRZFMQQXXJTTF-AVGNSLFASA-N 0.000 description 1
- SVSQSPICRKBMSZ-SRVKXCTJSA-N Lys-Pro-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O SVSQSPICRKBMSZ-SRVKXCTJSA-N 0.000 description 1
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
- 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- ULECEJGNDHWSKD-QEJZJMRPSA-N Phe-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 ULECEJGNDHWSKD-QEJZJMRPSA-N 0.000 description 1
- YVXPUUOTMVBKDO-IHRRRGAJSA-N Phe-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CS)C(=O)O YVXPUUOTMVBKDO-IHRRRGAJSA-N 0.000 description 1
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 1
- SWXSLPHTJVAWDF-VEVYYDQMSA-N Pro-Asn-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWXSLPHTJVAWDF-VEVYYDQMSA-N 0.000 description 1
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 1
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 1
- XKFJENWJGHMDLI-QWRGUYRKSA-N Ser-Phe-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O XKFJENWJGHMDLI-QWRGUYRKSA-N 0.000 description 1
- JLKWJWPDXPKKHI-FXQIFTODSA-N Ser-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)O JLKWJWPDXPKKHI-FXQIFTODSA-N 0.000 description 1
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 description 1
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 1
- JZRYFUGREMECBH-XPUUQOCRSA-N Ser-Val-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O JZRYFUGREMECBH-XPUUQOCRSA-N 0.000 description 1
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 1
- ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 1
- 230000017488 activation-induced cell death of T cell Effects 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention provides a preparation method of a protein 4-1BBL. In the preparation method, a recombinant protein 4-1BBL containing 206 amino acid residues (Arg 104-Glu 309) is prepared from an extracellular-segment protein of mouse 4-1BBL (TNFSF9 (Tumor Necrosis Factor Receptor Superfamily 9), NP_033430.1) by using a gene engineering method. By adopting the preparation method provided by the invention, a large quantity of proteins 4-1BBL can be obtained, so that the yield of the protein is greatly improved, and the obtained extracellular-segment protein 4-1BBL can be applied to preparation of kits for the quantitative pre-clinical researches of the protein 4-1BBL or for medicinal purposes and has a wide application prospect.
Description
(1) technical field
The present invention relates to a kind of preparation method of 4-1BBL albumen.
(2) background technology
4-1BB/4-1BBL is that another outside CD28/B7 is to important costimulatory signal molecule.4-1BB (CD137) belongs to Tumor Necrosis Factor Receptors (TNFR) superfamily, mainly be distributed in the surfaces such as T cell, NK cell and DC cell of activation, its part 4-1BBL (CD137L) is main to express on the T cell and some tumour cells of full-time APC cell (as mononuclear macrophage, DC cell, B cell), activation.4-1BBL is II type transmembrane glycoprotein, and molecular weight is 34KD, and people and mouse have 36% homology.
The 4-1BB/4-1BBL signal plays an important role to strengthening and keeping immunne response.Compare with the CD28/B7 signal transduction pathway, 4-1BB/4-1BBL is CD8 mainly in the later stage of immunne response
+The amplification of T cell clone, survival and memory are killed and wounded signal are provided, and it is more obvious that it stimulates acting on of T cell proliferation and secrete cytokines to show when lacking powerful CD28/B7 signal.The activation of 4-1BB is to CD4
+And CD8
+The T cell all has effect, but preferentially stimulates CD8
+The activation of T cell.Except passing through 4-1BB receptor for stimulating T extracellular, 4-1BBL also stimulates monocyte by its reverse signal conduction path, causes M-CSF to express and discharges cytokine profiles, the prolongation monocyte survival phase, promotes cell proliferation and mitotic division.
In recent years, the 4-1BB/4-1BBL signal transduction pathway has become a novel targets of immunotherapy of tumors design.In body, experiment shows, the necrocytosis (AICD) that the 4-1BB monoclonal antibody can prevent activation to induce, and the propagation of promotion lotus knurl host medium size lymphocyte, and selectivity promotes the secretion of I cytokines, the antitumor action of reinforcing effect cell.This antitumor action has memory to the attack again of tumour, confirms to have long-term anti tumor immune response to exist.In addition, without tumor growth, and exist and to resist the immunizing power that tumour is attacked again after the tumor cell inoculation mouse of transfection 4-1BBL.Research is also found, the specific CTL s that fusion rotein Ig-4-1BBL effectively induced tumor the same as the anti-4-1 bb antibody continues, treatment Mouse Liver colorectal carcinoma.
On the other hand, confirm in the research of therapeutic vaccine, the recombinant poxvirus of expressing 4-1BBL obviously strengthens the vaccine-induced mouse of HIV and produces take IFN-γ and reply specific C D8 as feature
+T cell response thisly acts on immunity and still can detect in rear 2 months.In the CEA-transgene mouse model, the 4-1BBL recombinant poxvirus obviously strengthens the therapeutic action of the recombinant poxvirus vaccine of expressing B7.1 and CEA, this effect and CEA specific C D4
+And CD8
+The t cell response level increases relevant.Report is arranged recently, can induce powerful cell response and anamnestic reaction with several costimulatory moleculeses that comprise 4-1BBL as the molecule adjuvant of DNA vaccination.Above result has all been showed the application prospect of 4-1BBL in human tumor and infectious diseases immunotherapy.
Prior art is directly extracted from histocyte the preparation method of 4-1BBL albumen, and yield is low, cost is high.Can not be widely used in vivo test or clinical.
(3) summary of the invention
In order to improve the yield of 4-1BBL albumen, reduce costs, provide a large amount of starting material for preparing preclinical test medication or diagnostic reagent, the cDNA that the invention provides a kind of employing 4-1BBL (TNFSF9, NP_033430.1) extracellular fragment albumen contains the method for the restructuring 4-1BBL albumen of 206 amino-acid residues (Arg 104-Glu 309) with the gene engineering method preparation.
The technical solution used in the present invention is:
A kind of preparation method of 4-1BBL albumen, described method comprises:
(1) get and contain 4-1BBL albumen
Mouse lymphocyte, the conA stimulated in vitro is cultivated by the trizol cracking, and extracting obtains mRNA; The raw materials used mouse lymphocyte that contains 4-1BBL albumen for routine;
(2) the mRNA reverse transcription is obtained the cDNA of 4-1BBL extracellular fragment albumen;
(3) step (2) gained cDNA is carried out pcr amplification, obtain 4-1BBL albumen goal gene; The pcr amplification primer is: upstream primer: 5 '-CTC GAG AAA AGA AGAACC GAG CCA AGA CCT-3 ', downstream primer: 5 '-GAA TTC TTC CCATGG ATT ATC AGG-3 ';
(4) with step (3) PCR product with the directed ppic9 that inserts through same double digestion after Xho I and EcoR I double digestion, obtain recombinant plasmid ppic9-4-1BBL;
(5) recombinant plasmid ppic9-4-1BBL is converted into bacillus coli DH 5 alpha, through cultivating amplification, extracting and purifying, sequencing analysis, obtains the correct recombinant plasmid of order-checking;
(6) will check order correct recombinant plasmid transformed to the methanol yeast bacterium, the abduction delivering recombinant protein;
(7) the activation bacterial strain that will express recombinant protein is induced fermentation culture, and fermented liquid is centrifugal, gets the supernatant liquor separation and purification, obtains the 4-1BBL recombinant protein of purifying.
the nucleotide sequence of step (5) recombinant plasmid ppic9-4-1BBL is as follows: CTC, GAG, AAAAGA, AGA, ACC, GAG, CCA, AGA, CCT, GCA, TTG, ACC, ATT, ACT, ACT, TCTCCA, AAC, TTG, GGT, ACA, AGA, GAA, AAC, AAC, GCT, GAC, CAG, GTCACT, CCA, GTT, TCT, CAC, ATC, GGA, TGT, CCA, AAC, ACC, ACC, CAG, CAGGGA, TCT, CCT, GTT, TTT, GCT, AAG, TTG, TTG, GCC, AAA, AAC, CAG, GCTTCT, TTG, TGT, AAC, ACT, ACC, TTG, AAC, TGG, CAC, TCT, CAA, GAC, GGTGCC, GGT, TCT, TCT, TAC, TTG, TCT, CAG, GGT, TTG, AGA, TAC, GAG, GAGGAC, AAG, AAG, GAG, TTG, GTC, GTC, GAC, TCT, CCT, GGA, TTG, TAC, TACGTC, TTT, TTG, GAG, TTG, AAG, TTG, TCT, CCA, ACA, TTC, ACC, AAC, ACTGGA, CAC, AAG, GTT, CAG, GGA, TGG, GTT, TCT, TTG, GTT, TTG, CAG, GCTAAG, CCA, CAG, GTT, GAC, GAT, TTC, GAC, AAT, TTG, GCC, TTG, ACT, GTCGAA, TTG, TTC, CCT, TGC, TCT, ATG, GAA, AAC, AAA, TTG, GTC, GAC, AGATCT, TGG, TCT, CAA, TTG, TTG, TTG, TTG, AAG, GCC, GGA, CAC, AGA, TTGTCT, GTC, GGA, TTG, AGA, GCA, TAC, TTG, CAT, GGT, GCA, CAA, GAC, GCTTAC, AGA, GAC, TGG, GAG, TTG, TCT, TAC, CCT, AAC, ACC, ACT, TCT, TTCGGT, TTG, TTC, TTG, GTT, AAA, CCT, GAT, AAT, CCA, TGG, GAA, GAA, TTC.
The aminoacid sequence of obtained recombinant protein is as follows:
RTEPRPALTITTSPNLGTRENNADQVTPVSHIGCPNTTQQGSPVFAKLLAKNQASLCNTTLNWHSQDGAGSSYLSQGLRYEEDKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVLQAKPQVDDFDNLALTVELFPCSMENKLVDRSWSQLLLLKAGHRLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVKPDNPWE。
Use the 4-1BBL albumen that the inventive method obtains, it is a New Set with highly sensitive, high specific, the 4-1BBL protein immune animal Dispersal risk that uses this invention technology to obtain, can make diagnostic kit, be used for pathogenesis, diagnosis, differential diagnosis and the prognosis of above-mentioned immune correlated disease animal model and the observation of curative effect.The 4-1BBL albumen that uses the present invention to make finished product can be used for preparation in early stage and the research of clinical medicine, uses and curative effect as the adjuvant of vaccine.Above concrete application mode belongs to common practise for those of ordinary skills, therefore repeats no more.
Beneficial effect of the present invention is mainly reflected in: adopt the inventive method, can obtain in a large number 4-1BBL albumen, greatly improved the albumen yield, the 4-1BBL extracellular fragment albumen of acquisition can be applied to prepare to the test kit of 4-1BBL protein quantification or medicinal, has a extensive future.
(4) description of drawings
Fig. 1 is that SDS-PAGE and the Western blot of 4-1BBL extracellular region protein analyzes; A:SDS-PAGE, 1:protein marker; 2: the yeast supernatant that empty plasmid transforms; The yeast supernatant of 3:4-1BBL recombinant plasmid transformed, target protein are the approximately tripolymer of 70KD of molecular weight; B:Western blot;
The attach most importance to analysis (cpm) of the short T cell proliferation experiment of H4-1BBL of Fig. 2;
Fig. 3 is the IL-2 level (ng/L) of mouse T cell 48h culture supernatant;
Fig. 4 is the IFN-γ level (ng/L) of mouse T cell 48h culture supernatant.
(5) embodiment
The present invention is described further below in conjunction with specific embodiment, but protection scope of the present invention is not limited in this:
The preparation of embodiment 1:4-1BBL albumen
(1) separate BALB/c mouse splenocyte (the aseptic BALB/c mouse spleen of getting, after grinding, crosses the glass nook closing member 150 eye mesh screens, obtain single cell suspension), the conA stimulated in vitro is cultivated (after the RPMI1640 washing, resuspended and adjust cell concn as 1 * 10 take the RPMI1640 (containing conA5 μ g/ml) that contains 10% foetal calf serum
6/ ml puts 37 ℃, 5% CO
2Condition is cultivated 72h, and collecting cell is used for extracting total RNA.) by the trizol cracking (0.1ml cell/1ml trizol, 42 ℃ 30~40min), extracting obtains mRNA;
(2) mRNA reverse transcription (Superscript II reverse transcription test kit is available from Invitrogen company) is obtained the cDNA of 4-1BBL extracellular fragment albumen;
(3) carry out pcr amplification take step (2) gained cDNA as template, obtain 4-1BBL albumen goal gene;
The pcr amplification primer is:
Upstream primer: 5 '-CTC GAG AAA AGA AGA ACC GAG CCA AGA
CCT-3’
Downstream primer: 5 '-GAA TTC TTC CCA TGG ATT ATC AGG-3 ';
The PCR reaction solution forms (Buffer, dNTP, DNA Polymerase are available from Invitrogen company):
ddH
2O 37.60μL
10×Buffer 5μL
dNTP mixture(2.5mM) 4μL
Upstream primer (20pmol/ μ L) 1 μ L
Downstream primer (20pmol/ μ L) 1 μ L
MgCl
2(25mM) 0.5μL
CDNA template (approximately 10
4Copy) 0.5 μ L
DNA Polymerase 0.4μL
The PCR reaction conditions:
Enter circulation after 95 ℃ of denaturing treatment 3min, 94 ℃ of 30S, 56 ℃ of 30S, 72 ℃ of 1min, 30 rear 72 ℃ of extension 7min of circulation;
(4) with step (3) PCR product directed ppic9 through same double digestion (NOVAGEN company buy) that inserts after with Xho I+EcoR I double digestion, obtain recombinant plasmid ppic9-4-1BBL;
(5) recombinant plasmid ppic9-4-1BBL is converted into bacillus coli DH 5 alpha, through cultivating amplification, extracting and purifying, also carrying out sequential analysis with full-automatic sequenator, obtains the correct recombinant plasmid (sequence is seen SEQ ID No.1) of order-checking;
(6) will check order correct recombinant plasmid transformed to methanol yeast bacterium (NOVAGEN company buy), cultivate (separation of supernatant after 2-YT substratum (containing kanamycin50 μ g/ml) cultivation in 96 hours under the condition of 28 ℃, separate each protein band with SDS-PAGE, and detect with Western Blot; Purified product is analyzed demonstration through 12% SDS-PAGE, approximately a special protein belt (Figure 1A) is arranged the 70kD vicinity at molecular weight, is indicated as the tripolymer of 4-1BBL self-assembling formation.Western blot result shows, this albumen mass-energy and goat-anti mouse 4-1BB L antibody are (available from R﹠amp; D company) hybridization forms the approximately monomer of 23KD of molecular weight after β ME processes, conform to expected results (Figure 1B).
(7) bacterial strain that will express recombinant protein is first drawn flat board (yeast SD solid medium) inoculation, and then amplification in liquid nutrient medium (yeast SD liquid nutrient medium), seed liquor 5% inoculum size by volume is linked in 2-YT substratum (containing kanamycin 50 μ g/ml), 28 ℃, 300r/min is more than high dissolved oxygen is cultured to 50OD.Induced 8 hours under high dissolved oxygen condition, put tank, centrifugal, get supernatant liquor and carry out the separation and purification operation:
A), supernatant liquor adopts the 0.45um membrane filtration, adds 1/2 volume H
2O is diluted to electricity and leads<5mS/cm, crosses anion-exchange column, and filler is Q XL (Amershame), balance liquid (50mMTris+2.5mMEDTA+0.1mMPMSF, pH7.6), elutriant are (50mMTris, 0.3MNaCl+2.5mMEDTA, pH7.6), one-step elution;
B), collect preparation of samples and cross hydrophobic chromatography, slowly stream adds 2 times of volumetric balance liquid (25mMPB+0.8M (NH
4)
2SO
4, pH7.4) to sample, stir simultaneously, filler is Phenyl HP, and elutriant is 25mMPB, and (A liquid is balance liquid to pH7.4, B liquid is elutriant, carry out drip washing and wash-out with the A+B mixed solution), the step gradient elution accounts for 60% (this accounts for the volume ratio of A+B mixed solution as B liquid) take elutriant, 70% drip washing, 90%, 100% wash-out, changing liquid is H
2O is wash-out again a time, all treats baseline stability before each wash-out.
C), SDS-PAGE as a result the display-object stripe size meet expection, in the end in single step purification, the foreign protein major part is worn in liquid at stream, wash-out can get purity sample preferably after drip washing.
D), collect 90% elution fraction and cross Sephadex G25 desalination, changing liquid is 25mMPB, pH7.4.
E), by immunoassay or biological activity determination 4-1BBL protein peak part, obtain the 4-1BBL extracellular fragment albumen (sequence is seen SEQ ID No.2) of purifying, freeze-drying is preserved.
The immunologic competence of embodiment 2:4-1BBL albumen
The 4-1BBL extracellular fragment albumen that adopts the inventive method to obtain, through stimulating the mouse T lymphocyte of vitro culture, can effectively strengthen T lymphopoiesis (enhancing rate relatively is 25.6%) and the cytokines such as secretion IL-2 (enhancing rate relatively is 53.2%), IFN-γ (enhancing rate relatively is 65.5%) of CD3 monoclonal antibody activation, show and have the collaborative hormesis of significant T cell (Fig. 2~Fig. 4).
Method: mouse boosting cell filters through nylon hair post and obtains the T lymphocyte, with 10
5/ mL T cell is inoculated in 96 orifice plates, set up 1 PBS control group and 3 experimental group (4-1BBL, the anti-CD28 of anti-CD3+, the anti-CD28 of the anti-CD3+ of 4-1BBL+), wherein 4-1BBL concentration is 1 μ g/mL, anti-CD3 and anti-CD28 (available from ebioscience company) concentration is 10 μ g/mL, and each group is established 3 multiple holes.At 37 ℃, 5%CO
2Cultivate 48h under condition, the collecting cell supernatant liquor detects respectively IL-2 and IFN-γ concentration with ELISA test kit (available from Diaclone company).Similarity condition is cultivated the T cell warp of 72h
3H-TdR method (reagent is available from Sigma company) detects T cell proliferation index (cpm).The data that in figure are three independent experiments represent with " means standard deviation ".
SEQUENCE LISTING
<110〉Hangzhou Pedagogic University
<120〉a kind of preparation method of 4-1BBL albumen
<130>
<160> 4
<170> PatentIn version 3.4
<210> 1
<211> 636
<212> DNA
<213> Unknown
<220>
<223〉artificial sequence
<400> 1
ctcgagaaaa gaagaaccga gccaagacct gcattgacca ttactacttc tccaaacttg 60
ggtacaagag aaaacaacgc tgaccaggtc actccagttt ctcacatcgg atgtccaaac 120
accacccagc agggatctcc tgtttttgct aagttgttgg ccaaaaacca ggcttctttg 180
tgtaacacta ccttgaactg gcactctcaa gacggtgccg gttcttctta cttgtctcag 240
ggtttgagat acgaggagga caagaaggag ttggtcgtcg actctcctgg attgtactac 300
gtctttttgg agttgaagtt gtctccaaca ttcaccaaca ctggacacaa ggttcaggga 360
tgggtttctt tggttttgca ggctaagcca caggttgacg atttcgacaa tttggccttg 420
actgtcgaat tgttcccttg ctctatggaa aacaaattgg tcgacagatc ttggtctcaa 480
ttgttgttgt tgaaggccgg acacagattg tctgtcggat tgagagcata cttgcatggt 540
gcacaagacg cttacagaga ctgggagttg tcttacccta acaccacttc tttcggtttg 600
ttcttggtta aacctgataa tccatgggaa gaattc 636
<210> 2
<211> 206
<212> PRT
<213> Unknown
<220>
<223〉artificial sequence
<400> 2
Arg Thr Glu Pro Arg Pro Ala Leu Thr Ile Thr Thr Ser Pro Asn Leu
1 5 10 15
Gly Thr Arg Glu Asn Asn Ala Asp Gln Val Thr Pro Val Ser His Ile
20 25 30
Gly Cys Pro Asn Thr Thr Gln Gln Gly Ser Pro Val Phe Ala Lys Leu
35 40 45
Leu Ala Lys Asn Gln Ala Ser Leu Cys Asn Thr Thr Leu Asn Trp His
50 55 60
Ser Gln Asp Gly Ala Gly Ser Ser Tyr Leu Ser Gln Gly Leu Arg Tyr
65 70 75 80
Glu Glu Asp Lys Lys Glu Leu Val Val Asp Ser Pro Gly Leu Tyr Tyr
85 90 95
Val Phe Leu Glu Leu Lys Leu Ser Pro Thr Phe Thr Asn Thr Gly His
100 105 110
Lys Val Gln Gly Trp Val Ser Leu Val Leu Gln Ala Lys Pro Gln Val
115 120 125
Asp Asp Phe Asp Asn Leu Ala Leu Thr Val Glu Leu Phe Pro Cys Ser
130 135 140
Met Glu Asn Lys Leu Val Asp Arg Ser Trp Ser Gln Leu Leu Leu Leu
145 150 155 160
Lys Ala Gly His Arg Leu Ser Val Gly Leu Arg Ala Tyr Leu His Gly
165 170 175
Ala Gln Asp Ala Tyr Arg Asp Trp Glu Leu Ser Tyr Pro Asn Thr Thr
180 185 190
Ser Phe Gly Leu Phe Leu Val Lys Pro Asp Asn Pro Trp Glu
195 200 205
<210> 3
<211> 30
<212> DNA
<213> Unknown
<220>
<223〉artificial sequence
<400> 3
ctcgagaaaa gaagaaccga gccaagacct 30
<210> 4
<211> 24
<212> DNA
<213> Unknown
<220>
<223〉artificial sequence
<400> 4
gaattcttcc catggattat cagg 24
Claims (1)
1. the preparation method of a 4-1BBL albumen, described method comprises:
(1) get the mouse lymphocyte that contains 4-1BBL albumen, the conA stimulated in vitro is cultivated by the trizol cracking, and extracting obtains mRNA;
(2) the mRNA reverse transcription is obtained the cDNA of 4-1BBL extracellular fragment albumen;
(3) step (2) gained cDNA is carried out pcr amplification, obtain 4-1BBL albumen goal gene; The pcr amplification primer is: upstream primer: 5 '-CTC GAG AAA AGA AGA ACC GAG CCA AGA CCT-3 ', downstream primer: 5 '-GAA TTC TTC CCA TGG ATT ATC AGG-3 ';
(4) with step (3) PCR product with the directed ppic9 that inserts through same double digestion after Xho I and EcoR I double digestion, obtain recombinant plasmid ppic9-4-1BBL;
(5) recombinant plasmid ppic9-4-1BBL is converted into bacillus coli DH 5 alpha,, through cultivating amplification, extracting and purifying, sequencing analysis, obtains the correct recombinant plasmid of order-checking; The recombinant plasmid ppic9-4-1BBL sequence is as follows: CTC GAG AAA AGA AGA ACC GAG CCA AGA CCT GCA TTG ACC ATT ACT ACT TCT CCA AAC TTG GGT ACA AGA GAA AAC AAC GCT GAC CAG GTC ACT CCA GTT TCT CAC ATC GGA TGT CCA AAC ACC ACC CAG CAG GGA TCT CCT GTT TTT GCT AAG TTG TTG GCC AAA AAC CAG GCT TCT TTG TGT AAC ACT ACC TTG AAC TGG CAC TCT CAA GAC GGT GCC GGT TCT TCT TAC TTG TCT CAG GGT TTG AGA TAC GAG GAG GAC AAG AAG GAG TTG GTC GTC GAC TCT CCT GGA TTG TAC TAC GTC TTT TTG GAG TTG AAG TTG TCT CCA ACA TTC ACC AAC ACT GGA CAC AAG GTT CAG GGA TGG GTT TCT TTG GTT TTG CAG GCT AAG CCA CAG GTT GAC GAT TTC GAC AAT TTG GCC TTG ACT GTC GAA TTG TTC CCT TGC TCT ATG GAA AAC AAA TTG GTC GAC AGA TCT TGG TCT CAA TTG TTG TTG TTG AAG GCC GGA CAC AGA TTG TCT GTC GGA TTG AGA GCA TAC TTG CAT GGT GCA CAA GAC GCT TAC AGA GAC TGG GAG TTG TCT TAC CCT AAC ACC ACT TCT TTC GGT TTG TTC TTG GTT AAA CCT GAT AAT CCA TGG GAA GAA TTC;
(6) will check order correct recombinant plasmid transformed to the methanol yeast bacterium, the abduction delivering recombinant protein;
(7) the activation bacterial strain that will express recombinant protein is induced fermentation culture, and fermented liquid is centrifugal, gets the supernatant liquor separation and purification, obtains the 4-1BBL recombinant protein of purifying.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110045245 CN102174522B (en) | 2011-02-24 | 2011-02-24 | Preparation method of protein 4-1BBL |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110045245 CN102174522B (en) | 2011-02-24 | 2011-02-24 | Preparation method of protein 4-1BBL |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102174522A CN102174522A (en) | 2011-09-07 |
CN102174522B true CN102174522B (en) | 2013-11-06 |
Family
ID=44517776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110045245 Expired - Fee Related CN102174522B (en) | 2011-02-24 | 2011-02-24 | Preparation method of protein 4-1BBL |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102174522B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103713125B (en) * | 2014-01-08 | 2015-12-30 | 滨州医学院 | A kind of for detect malignant hematologic disease CD137L suddenly change kit and application |
CN111607571B (en) * | 2019-02-26 | 2022-08-30 | 南京惟亚德生物医药有限公司 | Replicative oncolytic adenovirus for specifically activating immune co-stimulation pathway and preparation method and application thereof |
CN111606999B (en) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | Replicative oncolytic adenovirus with functions of activating immune co-stimulatory signaling pathway and blocking immune checkpoint and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1844149A (en) * | 2005-04-07 | 2006-10-11 | 苏州大学 | Monoclonal antibody against human 4-1BBL and its use |
CN1976946A (en) * | 2004-07-03 | 2007-06-06 | 财团法人牧岩生命工学研究所 | Supertype epitopes, oligonucleotides coding the same which induce effective CTL response against HCV and the use thereof |
CN101684456A (en) * | 2008-09-28 | 2010-03-31 | 江门罗森生物制药有限公司 | Method for amplifying NK cells of human beings under condition of in vitro culture |
-
2011
- 2011-02-24 CN CN 201110045245 patent/CN102174522B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1976946A (en) * | 2004-07-03 | 2007-06-06 | 财团法人牧岩生命工学研究所 | Supertype epitopes, oligonucleotides coding the same which induce effective CTL response against HCV and the use thereof |
CN1844149A (en) * | 2005-04-07 | 2006-10-11 | 苏州大学 | Monoclonal antibody against human 4-1BBL and its use |
CN101684456A (en) * | 2008-09-28 | 2010-03-31 | 江门罗森生物制药有限公司 | Method for amplifying NK cells of human beings under condition of in vitro culture |
Also Published As
Publication number | Publication date |
---|---|
CN102174522A (en) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2067031C (en) | Dna coding for human cell surface antigen | |
CN109134665A (en) | A kind of BCMA Chimeric antigen receptor and application based on single domain antibody | |
CN111925451B (en) | BCMA (brain cell activating antigen) -targeted Chimeric Antigen Receptor (CAR) and application thereof | |
CN105647939A (en) | Glycosylated IL-7, preparation and uses | |
CN104788567B (en) | A kind of bispecific antibody preparation method and application of targeted mouse T lymphocyte CD3 and human tumor antigen EpCAM | |
CN109468284A (en) | A kind of immunocyte of the dual Chimeric antigen receptor gene modification based on CD19 and PSMA and its application | |
CN109468283A (en) | A kind of immunocyte of the dual Chimeric antigen receptor gene modification based on CD19 and BCMA and its application | |
CN112480239B (en) | Human papilloma virus specific T cell receptor and anti-tumor application thereof | |
WO2022007795A1 (en) | Chimeric antigen receptor and use thereof | |
US10875903B2 (en) | Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof | |
CN107365798A (en) | A kind of CD19 CAR T cells of carrying iCasp9 suicide genes and its application | |
CN114478806B (en) | Chimeric receptor for improving killing activity of immune cells and application thereof | |
CN112500497B (en) | CLTX-NKG2D bispecific chimeric antigen receptor cell and preparation method and application thereof | |
KR20190094106A (en) | A novel polyvalent HPV vaccine composition | |
CN108753774A (en) | Interfere CD19-CAR-T cells and its application of IL-6 expression | |
CN110343667A (en) | Immunocyte of engineering and its preparation method and application | |
CN102174522B (en) | Preparation method of protein 4-1BBL | |
CN101041816B (en) | Artificial antigen presenting cell and preparation method thereof | |
US20210046113A1 (en) | Dual-activating costimulatory molecule receptor and use thereof | |
CN101698852B (en) | Protein or polypeptide with function of CD137L, and gene and application thereof | |
KR20190094107A (en) | A novel vaccine adjuvant | |
CN115286698B (en) | Use of antigen short peptide for screening medicine for treating HPV related diseases and screened TCR thereof | |
CN111499766A (en) | Immune effector cell aiming at chronic lymphocytic leukemia, preparation method and application thereof | |
EP4299592A1 (en) | Co-expressed cxcr2 and t cells of star specific to gpc3, and use thereof | |
CN108997489B (en) | Interferon mutant and interferon mutant fusion antibody, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131106 Termination date: 20160224 |